Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Geron Q3 2026 Results: Turns Profitable, Net Income $1.35M

Geron Corporation reported a net income of $1.35 million for the third quarter of 2026, a significant improvement from the $18.4 million net loss in the same period of 2025, driven by a 27% increase in product revenue to $60.1 million. Despite the quarterly profit, the company recorded a net loss of $19.0 million for the first nine months of 2026 as it continues to manage high operating expenses and inventory investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue60.247.2
Net income1.4-18.4
EPS (diluted, $ a share)$0.00$-0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+27.4%
Operating margin9.6%
Source

10-Q filed with the SEC, NASDAQ: GERN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Geron Corp: key numbers

Share price
$0.9419Close, Nov 16
Market cap
$607M
Shares outstanding
644.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Geron Corp

All →
7:13 AM ET 8-K
Financial Results

Geron Financial Results

Geron Corporation reported third quarter 2026 financial results, highlighted by $60.1 million in RYTELO net product revenue, a 5% increase over the prior quarter. The company reiterated its full-year RYTELO revenue guidance at the mid-to-high end of $220-$240 million and initiated a gated commercial launch in Europe, with availability expected in Germany by year-end.

Term
Q3 2026

“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”

Harout Semerjian, President and Chief Executive Officer of Geron
4:48 PM ET 8-K
Clinical Trial Data

Geron Clinical Trial Data

Geron Corporation is discontinuing its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, although no new safety signals were observed.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.